Safety, tolerability and weight reduction findings of oral amycretin: a novel amylin and glucagon-like peptide-1 receptor co-agonist, in a first-in-human study
Results: At week 12, the mean change in body weight (amycretin 50 mg, -10.4% [SD, 4.6]; amycretin 2×50 mg, -13.1% [SD, 4.8]) was...